|Seacoast Science Center|
Even though we had about a hundred pounds of leftovers in the fridge, we stopped on the way home on Friday at Markey's Lobster Pound to gorge ourselves on lobsters, steamers, oysters on the half shell, fried clams, and french fries. I'm not sure why we did that, but it sure was delicious! The Hell with the leftovers!
We are departing from our usual norm this Christmas. Instead of our long-standing tradition of hosting Christmas at our house, we plan to go to Brian and Pam's home in South Orange. We're not even getting a Christmas tree this year! I'm having withdrawal symptoms already. I don't think I've ever not had a Christmas tree in my entire life! Jeff, Christine, and Jason may be able to join us in New Jersey (I hope). I know the Santa Claus thing can be overdone, but I'm really looking forward to seeing Logan on Christmas morning. The magic of these years won't last for long.
In my last post, I shared that the FDA had just approved daratumumab (Darzalex) as the first MM immunotherapy drug. Well, they didn't stop there. On November 20, ixazomib (trade name Ninlaro) was approved for patients with at least one prior therapy! As you well know, that was my front line Phase I clinical trial therapy in 2011. I knew it then as MLN-9708. I'm really pleased that I was able to participate in that clinical trial, that it worked so well for me, and that it has now been approved as a viable therapy option for all Multiple Myeloma patients. It's exciting to have this oral proteasome inhibitor as an alternative to Velcade, both because of the convenience of not having to visit the clinic for infusions and for its lower side effects. It may even work better than Velcade. However, there may be a fly in the ointment. Most insurance plans cover infusion therapies for cancer, but some do not cover oral remedies under their prescription drug plans. That's a real bummer. Hopefully, this issue can be resolved so that Ninlaro may be made available to all those who need it.
But wait! There's more! Today, the FDA approved the second immunotherapy drug, elotuzumab (Empliciti), for MM patients with one to three prior therapies! Wow! This makes the third MM therapy drug approved by the FDA in the last three weeks and the fourth one this year. This is such amazing news for us MM patients. Our options for future treatments have expanded greatly. It is a great cause for optimism and another reason to be thankful this holiday season.